Purpose

The main purpose of this study is to characterize the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Condition

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis - Women must not be pregnant, lactating, or breastfeeding

Exclusion Criteria

  • Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study. - To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BMS-986165
  • Drug: BMS-986165
    Participants will receive BMS-986165 in tablet form

Recruiting Locations

The Kirklin Clinic of UAB Hospital
Birmingham, Alabama 35233
Contact:
Boni Elewski, Site 0278

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

Rachel Peterson
+1 619 293 6213
PetersonRachel@prahs.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.